Lilly's osteoporosis drug meets late-stage trial goals

04/8/2009 | Bloomberg · Reuters

Eli Lilly and Co. reported data from a second Phase III study showing that postmenopausal women who took arzoxifene, a drug candidate for osteoporosis, had increased bone-mineral density in the hips and spine compared with those who got placebo. Lilly said it plans to seek FDA clearance for the treatment and conclude another trial involving 9,000 patients later this year.

View Full Article in:

Bloomberg · Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ